Literature DB >> 23880682

Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases.

Shaul Atar1, Alice Wishniak2, Alexander Shturman3, Sewaed Shtiwi4, Marc Brezins3.   

Abstract

Several new oral anticoagulants have been approved for thromboembolism prevention in patients with nonvalvular atrial fibrillation. However, they are not yet approved for anticoagulation use in patients with prosthetic mechanical valves, and no randomized data have been published so far on their safety of use in these patients. We present two cases of patients with prosthetic mechanical mitral valves who were switched from warfarin and acenocoumarol to dabigatran and within 1 month experienced severe valve complications resulting in death. One patient experienced stroke and later cardiogenic shock and death, and the other experienced pulmonary edema, cardiogenic shock, and subsequent death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23880682     DOI: 10.1378/chest.12-2486

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Dabigatran for mechanical valves.

Authors:  Patricia A Howard
Journal:  Hosp Pharm       Date:  2014-04

Review 2.  Potential use of NOACs in developing countries: pros and cons.

Authors:  Durga Bista; Leanne Chalmers; Luke Bereznicki; Gregory Peterson
Journal:  Eur J Clin Pharmacol       Date:  2014-05-11       Impact factor: 2.953

Review 3.  Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.

Authors:  Luigi Di Biase
Journal:  J Am Heart Assoc       Date:  2016-02-18       Impact factor: 5.501

4.  Assessment of novel oral anticoagulant use within a community teaching hospital.

Authors:  Sultan Alghadeer; Lori Hornsby
Journal:  Saudi Pharm J       Date:  2016-02-15       Impact factor: 4.330

Review 5.  Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.

Authors:  Konstantinos N Aronis; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2018-01-26       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.